Deubiquitination of Abelson tyrosine kinase: A novel regulatory mechanism targeting non-small cell lung cancer glycolysis

Tong Yu, Shuxia Jiang, Hongli Shan

PDF
Clinical and Translational Discovery ›› 2024, Vol. 4 ›› Issue (1) : e266. DOI: 10.1002/ctd2.266
COMMENTARY

Deubiquitination of Abelson tyrosine kinase: A novel regulatory mechanism targeting non-small cell lung cancer glycolysis

Author information +
History +

Abstract

In this commentary, we briefly introduce the importance of metabolic reprogramming in non-small celllung cancer (NSCLC) and the role of aberrant glycolysis processes intumorigenesis and metastasis. We further summarize the regulation of deubiquitylation modification on glycolysis-related kinases in this system. Andwe discusse the major discovery the research by He Yuanming et al. published in Clinical and Translational Medicine.Their study demonstrates targeting the USP7-c-Abl-HK2 axis represents a promising therapeutic strategt for NSCLC.

Keywords

c-Abl / Deubiquitylation / Glycolysis / NSCLC

Cite this article

Download citation ▾
Tong Yu, Shuxia Jiang, Hongli Shan. Deubiquitination of Abelson tyrosine kinase: A novel regulatory mechanism targeting non-small cell lung cancer glycolysis. Clinical and Translational Discovery, 2024, 4(1): e266 https://doi.org/10.1002/ctd2.266

References

[1]
Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72(5):409-436.
[2]
Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345-1356.
[3]
Faubert B, Li KY, Cai L, et al. Lactate metabolism in human lung tumors. Cell. 2017;171(2):358-371. e359.
[4]
Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27-47.
[5]
Yu T, Liu Y, Xue J, et al. Gankyrin modulated non-small cell lung cancer progression via glycolysis metabolism in a YAP1-dependent manner. Cell Death Discov. 2022;8(1):312.
[6]
Meng YM, Jiang X, Zhao X, et al. Hexokinase 2-driven glycolysis in pericytes activates their contractility leading to tumor blood vessel abnormalities. Nat Commun. 2021;12(1):6011.
[7]
Shen C, Xuan B, Yan T, et al. m(6)A-dependent glycolysis enhances colorectal cancer progression. Mol Cancer. 2020;19(1):72.
[8]
Kovacs K, Decatur C, Toro M, et al. 2-Deoxy-Glucose downregulates endothelial AKT and ERK via interference with N-linked glycosylation, induction of endoplasmic reticulum stress, and GSK3beta activation. Mol Cancer Ther. 2016;15(2):264-275.
[9]
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033.
[10]
Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell Metab. 2022;34(3):355-377.
[11]
He Y, Jiang S, Zhong Y, et al. USP7 promotes non-small-cell lung cancer cell glycolysis and survival by stabilizing and activating c-Abl. Clin Transl Med. 2023;13(12):e1509.
[12]
Zhao M, Huang C, Yang L, et al. SYVN1-mediated ubiquitylation directs localization of MCT4 in the plasma membrane to promote the progression of lung adenocarcinoma. Cell Death Dis. 2023;14(10):666.
[13]
Sheryazdanova A, Amoedo ND, Dufour S, Impens F, Rossignol R, Sablina A. The deubiquitinase OTUB1 governs lung cancer cell fitness by modulating proteostasis of OXPHOS proteins. Biochim Biophys Acta Mol Basis Dis. 2023;1869(7):166767.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
PDF

Accesses

Citations

Detail

Sections
Recommended

/